Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling
-
AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth
-
Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The "Biosimilars Market Outlook 2026-2034: Market Share, and Growth Analysis" report has been added to ResearchAndMarkets.com's offering.The Biosimilars...
-
Dublin, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The "Biologics Global Market Opportunities And Strategies To 2034" has been added to ResearchAndMarkets.com's offering. The biologics market report...
-
AEON Biopharma Reports Positive and Robust Biosimilarity Results: Identical Amino Acid Sequence and Highly Similar Functional Analysis Data
-
AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes
-
Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Biosimilar Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...
-
Dublin, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The "United States Peptide Therapeutics (Retail Side) Market by Region, Competition, Forecast & Opportunities, 2020-2030F" report has been added to ...
-
Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "Biosimilar Contract Manufacturing Market Size, Share & Trends Analysis Report by Source (Mammalian, Non-mammalian), Therapeutic Area (Oncology,...
-
AEON Biopharma Announces FDA BPD Type 2a Meeting for ABP-450 on November 19